European Association of Nuclear Medicine (EANM) response to the proposed ASTRO's framework for radiopharmaceutical therapy curriculum development for trainees.
Radiopharmaceuticals; Humans; Radiopharmaceuticals/therapeutic use; Radionuclide Imaging; Societies, Medical; Curriculum; Europe; Nuclear Medicine/education; Nuclear Medicine; Radiology, Nuclear Medicine and Imaging; General Medicine
Disciplines :
Radiology, nuclear medicine & imaging
Author, co-author :
Dierckx, Rudi; Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
Herrmann, Ken; Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany
Hustinx, Roland ; Centre Hospitalier Universitaire de Liège - CHU > > Service médical de médecine nucléaire et imagerie onco
Lassmann, Michael; Department of Nuclear Medicine, University Würzburg, Würzburg, Germany
Wadsak, Wolfgang; Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria ; Center for Biomarker Research in Medicine (CBmed GmbH), Graz, Austria
Kunikowska, Jolanta ; Nuclear Medicine Department, Medical University of Warsaw, ul. Banacha 1 a, 02-097, Warsaw, Poland. jolanta.kunikowska@wum.edu.pl
Language :
English
Title :
European Association of Nuclear Medicine (EANM) response to the proposed ASTRO's framework for radiopharmaceutical therapy curriculum development for trainees.
Publication date :
December 2022
Journal title :
European Journal of Nuclear Medicine and Molecular Imaging
ISSN :
1619-7070
eISSN :
1619-7089
Publisher :
Springer Science and Business Media Deutschland GmbH, Germany
WW has received research grants from ITM S.E., Scintomics, EZAG, Novo Nordisk (all institutional fees), consultancy fees from GE Healthcare (personal fees) and is a part-time employee of CBmed GmbH, Graz, Austria, and a founder and co-owner of MINUTE medical GmbH, Vienna, Austria.KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, personal fees from Pharma15, personal fees from Debiopharm, personal fees from AstraZeneca, personal fees from Janssen, outside the submitted work.
Kiess AP, Hobbs RF, Bednarz B, Knox SJ, Meredith R, Escorcia FE. ASTRO’s framework for radiopharmaceutical therapy curriculum development for trainees. Int J Radiat Oncol Biol Phys. 2022;113(4):719–26. 10.1016/j.ijrobp.2022.03.018. DOI: 10.1016/j.ijrobp.2022.03.018
Goldsmith SJ. Targeted radionuclide therapy: a historical and personal review. Semin Nucl Med. 2020;50:87–97. 10.1053/j.semnuclmed.2019.07.006. DOI: 10.1053/j.semnuclmed.2019.07.006
Rowe SP, Pomper MG. Molecular imaging in oncology: current impact and future directions. CA Cancer J Clin. 2022;72(4):333–52. 10.3322/caac.21713. DOI: 10.3322/caac.21713
Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19(8):534–50. 10.1038/s41571-022-00652-y. DOI: 10.1038/s41571-022-00652-y
Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 2020;21(3):e146–56. 10.1016/S1470-2045(19)30821-6. DOI: 10.1016/S1470-2045(19)30821-6
O Sartor, J de Bono, KN Chi, K Fizazi, K Herrmann, et al for the VISION Investigators177Lutetium-–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385. 1091–1103. https://doi.org/10.1056/NEJMoa2107322.
EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978–94–92671–16–5.
Aerts A, Eberlein U, Holm S, Hustinx R, Konijnenberg M, Strigari L, et al. EANM position paper on the role of radiobiology in nuclear medicine. Eur J Nucl Med Mol Imaging. 2021;48:3365–77. 10.1007/s00259-021-05345-9. DOI: 10.1007/s00259-021-05345-9
Pouget JP., Konijnenberg M, Eberlein U, Glatting G, Gabina PM, Herrmann K et al, EANM position paper on advancing radiobiology for shaping the future of nuclear medicine. Eur J Nucl Med Mol Imaging 2022; 2022 https://doi.org/10.1007/s00259-022-05934-2.
Herrmann K, Giovanella L, Santos A, Gear J, Kiratli PO, Kurth J, et al. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. Eur J Nucl Med Mol Imaging. 2022;49:2300–9. 10.1007/s00259-022-05785-x. DOI: 10.1007/s00259-022-05785-x
